Educational content on VJHemOnc is intended for healthcare professionals only. By visiting this website and accessing this information you confirm that you are a healthcare professional.

The Multiple Myeloma Channel is supported with funding from BMS (Gold) and Legend Biotech (Bronze).

VJHemOnc is an independent medical education platform. Supporters, including channel supporters, have no influence over the production of content. The levels of sponsorship listed are reflective of the amount of funding given to support the channel.

Share this video  

IMW 2019 | Issues within maintenance therapy standardization in MM

Giada Bianchi • 15 Sep 2019
IMW 2019
Multiple Myeloma

Giada Bianchi, MD, Dana-Farber Cancer Institute, Boston, MA, outlines the financial and geographical implications of the availability of maintenance therapy drugs for multiple myeloma (MM), speaking at the International Myeloma Workshop (IMW) 2019, held in Boston, MA.

More from Giada Bianchi

First-in-human study of autologous memory-like NK cells in patients with MRD+ multiple myeloma
1:30
First-in-human study of autologous memory-like NK cells in patients with MRD+ multiple myeloma
Giada Bianchi • 29 Sep 2023
Novel laboratory-based therapeutic approach in AL amyloidosis: investigating FLC secretion
1:53
Novel laboratory-based therapeutic approach in AL amyloidosis: investigating FLC secretion
Giada Bianchi • 29 Sep 2023
Investigating the proteasome stress response as a potential novel therapeutic target in myeloma
1:48
Investigating the proteasome stress response as a potential novel therapeutic target in myeloma
Giada Bianchi • 29 Sep 2023
The impact of CHIP in patients with AL amyloidosis
1:52
The impact of CHIP in patients with AL amyloidosis
Giada Bianchi • 29 Sep 2023

Related Videos

Updated results from the iMMagine-1 trial of anito-cel in R/R multiple myeloma
4:32
Updated results from the iMMagine-1 trial of anito-cel in R/R multiple myeloma
Giada Bianchi • 18 Dec 2025
Investigating AZD0120, a dual-targeting CAR-T product, in R/R myeloma: DURGA-1 preliminary results
3:36
Investigating AZD0120, a dual-targeting CAR-T product, in R/R myeloma: DURGA-1 preliminary results
Giada Bianchi • 7 Dec 2025
A Phase II trial investigating IberKDd in R/R multiple myeloma: the ReKInDLE study
3:11
A Phase II trial investigating IberKDd in R/R multiple myeloma: the ReKInDLE study
Giada Bianchi • 7 Dec 2025
Remote therapeutic monitoring reduces infection-related hospitalizations in hematologic cancers
4:04
Remote therapeutic monitoring reduces infection-related hospitalizations in hematologic cancers
Giada Bianchi • 15 Dec 2025
The content of VJHemOnc is intended for healthcare professionals